Venu G. Pillarisetty, MD, FACS
Faculty Investigator Profile: Venu G. Pillarisetty, MD, FACS
![]() |
|
RESEARCH INTERESTS
The goal of the UW TIME Lab is to develop a precise understanding of the nature of the adaptive immune response to solid tumors, in order to develop effective immunotherapies. While much of our work focuses on pancreatic and colorectal carcinoma, we are particularly interested in shedding light on aspects of tumor biology that reach across many tumor types. Our central goal is to address is how the immunosuppressive microenvironment created by solid tumors can be altered to enable reactivation of endogenous T cell responses. In concert with this work, we are also finding that adoptively transferred T cells (e.g. CAR-T cells) are subject to similar mechanisms of immunosuppression in the TIME.
COLLABORATORS
Nick Crispe
Professor of Pathology
Adjunct Professor of Immunology
University of Washington
Albert Folch
Professor of Engineering
University of Washington
Taran Gujral
Assistant Professor
Fred Hutchinson Cancer Center
Steven Katz
Chairman, Immuno-oncology Institute (Ix2)
Chief, Immunotherapy Service, Department of Medicine
Associate Professor of Surgery
Roger Williams Medical Center
Teresa Kim
Assistant Professor of Surgery
Co-PI, UW TIME Lab
University of Washington
Jonathan Liu
Associate Professor, Mechanical Engineering
Adjunct Associate Professor, Bioengineering
Adjunct Associate Professor, Laboratory Medicine and Pathology
University of Washington
Joshua Veatch
Acting Instructor, Department of Medicine
Fred Hutchinson Cancer Center
University of Washington
Raymond Yeung
Professor of Surgery
University of Washington
FUNDING
Department of Defense – United States Army Medical Research Acquisition Activity
Novel Therapeutics for Fibrolamellar Carcinoma
NIH 1R01CA181445-06
Interrogating the response of the tumor microenvironment to combination immunotherapy using a microfluidic platform
Fibrolamellar Cancer Foundation
Modulating stromal-immune cell interactions to activate anti-tumor immunity to fibrolamellar carcinoma
Ipsen Biopharmaceuticals
A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
NGM Biopharmaceuticals
Modulating myeloid cells in pancreatic ductal adenocarcinoma and microsatellite-stable colorectal cancer
Merck Investigator Studies Program
Defining and overcoming mechanisms of resistance to pembrolizumab in pancreatic ductal adenocarcinoma and microsatellite-stable colorectal cancer
Seattle Translational Tumor Research (STTR)
Defining the response of tumor slice cultures to chemotherapy and immunotherapy
AstraZeneca
Tumor slice culture evaluation of glypican-3-targeted CAR-T cells against hepatocellular carcinoma
Brotman Baty Institute for Precision Medicine
Identification and characterization of tumor-specific T cells in pancreatic ductal adenocarcinoma
Brotman Baty Institute for Precision Medicine
Defining the single cell transcriptomic response to immunotherapy using tumor slice cultures
MORE INFORMATION
Profile last updated on October 21, 2025

